Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?-Reference-Cited by-同舟云学术

Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?

Published:2010-07-14 Issue:5 Volume:2 Page:331-342
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Dirix L.Y.¹,Van Dam P.A.²,Prove A.M.²,Vermeulen P.B.²

Affiliation:

1. Oncology Center, St. Augustinus Hospital, Oosterveldlaan 24, 2610 Wilrijk-Antwerp, Belgium,

2. Breast Cancer Clinic, Translational Cancer Research Group-Antwerp, Cancer Center, Sint-Augustinus, Antwerp, Belgium

Abstract

Vast preclinical and clinical evidence has made angiogenesis one of the hallmarks of cancer. In many human tumours, vascular endothelial growth factor (VEGF) has been identified as the crucial mediator of this process. Initial studies suggested that angiogenesis, and VEGF in particular, could be inhibited without the risk of major side effects. After the pivotal data in first-line studies in patients with colorectal cancer, numerous clinical trials have been undertaken in patients with breast cancer. This review attempts to update these investigations and define the role of anti-VEGF antibody treatment in advanced breast cancer.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1758834010376301

Reference75 articles.

1. A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers

2. Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer

3. VEGF kinase inhibitors: how do they cause hypertension?

4. Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease

5. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short-term study on in-use stability of opened bevacizumab biosimilar PF-06439535 vials;European Journal of Hospital Pharmacy;2022-07-19

2. Adjuvant Molecular Therapies in Breast Cancer;Breast Cancer Management for Surgeons;2017-09-11

3. Rolipram potentiates bevacizumab-induced cell death in human glioblastoma stem-like cells;Life Sciences;2017-03

4. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer;Journal of Cellular Physiology;2016-11-30

5. Bevacizumab beyond progression in breast cancer;The Lancet Oncology;2014-10